title: Blood pressure in the first year of life in children with congenital adrenal hyperplasia due to 21-hydroxylase deficiency: a pilot study.
abstract: OBJECTIVE
  Evaluation of blood pressure in the first year of life in children with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency.
  
  
  METHODS
  Twenty-four children were included. Retrospective blood pressure values, fludrocortisone dosages, and serum renin, 17-hydroxyprogesterone (17-OHP) and androstenedione levels in the first year of life were evaluated. Blood pressure values were compared to reference values. Correlations between blood pressures and serum renin levels, and the dosage of fludrocortisone were calculated.
  
  
  RESULTS
  Mean peak systolic blood pressure values were generally not elevated, most values were around the 50th percentile, except incidentally higher mean peak systolic blood pressure values most below the 95th percentile. No significant correlations between blood pressure and serum renin, androstenedione and 17-OHP levels and fludrocortisone dosage were found.
  
  
  CONCLUSIONS
  In this pilot study in CAH patients, blood pressure values do not seem to be elevated in the first year of life. Further investigations are necessary to evaluate blood pressure in the first year of life in CAH patients in more detail.
authors.affiliation: Department of Paediatric Endocrinology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
authors.forename: Christiaan F
authors.initials: CF
authors.lastname: Mooij
authors.forename: Livia
authors.initials: L
authors.lastname: Kapusta
authors.forename: Barto J
authors.initials: BJ
authors.lastname: Otten
authors.forename: Hedi L
authors.initials: HL
authors.lastname: Claahsen-van der Grinten
mesh_terms: D019326:17-alpha-Hydroxyprogesterone / Q000097:blood; D000312:Adrenal Hyperplasia, Congenital / Q000188:drug therapy / Q000201:enzymology* / Q000503:physiopathology*; D000483:Alleles; D000735:Androstenedione / Q000097:blood; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001794:Blood Pressure / Q000502:physiology*; D004247:DNA / Q000235:genetics; D004252:DNA Mutational Analysis; D005260:Female; D005438:Fludrocortisone / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D010865:Pilot Projects; D012083:Renin / Q000097:blood; D012189:Retrospective Studies; D013255:Steroid 21-Hydroxylase / Q000378:metabolism*
chemical_list: D000893:Anti-Inflammatory Agents; D000735:Androstenedione; D019326:17-alpha-Hydroxyprogesterone; D004247:DNA; D013255:Steroid 21-Hydroxylase; D012083:Renin; D005438:Fludrocortisone